close

Endeavor BioMedicines gains rights to lead ULK1/2 inhibitor molecule

Endeavor BioMedicines gains rights to lead ULK1/2 inhibitor molecule Endeavor BioMedicines, a clinical-stage precision medicine company targeting the core drivers of multiple terminal diseases, including oncology and fibrosis, has concluded an exclusive licensing agreement with the Salk Institute, along with Sanford Burnham Prebys. Under the license agreement, the California-based company…..

TreeFrog Therapeutics secures $75M in Series B financing to advance a pipeline of stem cell-derived cell therapies

TreeFrog Therapeutics secures $75M in Series B financing to advance a pipeline of stem cell-derived cell therapies TreeFrog Therapeutics, a privately held French-based biotech startup focused on developing safe and affordable stem cell-derived cell therapies for millions of patients, today announced the successful closing of a $75 million (€64M) Series…..